PRKDC and neoplasm: Numerous compounds are in clinical testing to evaluate the efficacy of targeting DNA-PK (NCT02516813, NCT02316197, NCT01353625, and NCT02833883) and could offer the opportunity to design clinical trials around the concept of inhibiting DNA-PK activity to promote tumor immunogenicity in the setting of therapy-resistant tumors.